Across TCGA pan-cancer cohorts, ZDBF2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZDBF2 data layer compared with 22 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZDBF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZDBF2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where ZDBF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	1.000	0.230	.030	8	view →
PDAC	OS	Quartile	II,III,IV	0.822	0.276	.020	7	view →
LSCC	DFS	Median	All	0.578	0.818	.028	4	view →
GBM	OS	Tertile	All	0.474	0.301	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZDBF2 tumor-vs-normal RNA expression · all ZDBF2 data types